Preferred Label : METTL-3 Inhibitor STC-15;
NCIt synonyms : Methyltransferase-like Protein 3 STC-15;
NCIt definition : An orally bioavailable methyltransferase-like protein 3 (METTL-3) inhibitor, with
potential antineoplastic activity. Upon oral administration, METTL-3 inhibitor STC-15
targets, binds to and blocks the activity of METTL-3, thereby depleting N-6-methyladenosine
(m6A) depositions by METTL3 from certain mRNA transcripts. This leads to the formation
of double-stranded RNA, the activation of RNA sensors and the upregulation of expression
of genes associated with innate immunity, such as interferon (IFN). This causes upregulation
of cytokines and the expression of interferon stimulated genes (ISG). This abrogates
the METTL-3-mediated inhibition of certain immune cell functions and causes activation
of anti-tumor immune responses, primarily the activation of cytotoxic T-lymphocytes
in the tumor microenvironment (TME). In addition, by depleting m6A depositions by
METTL3 on certain mRNA transcripts, STC-15 negatively affects the stability and translation
of certain mRNAs leading to a decrease of the expression of certain tumor-associated
and anti-apoptotic genes. STC-15 also inhibits the function of leukemia stem cells.
METTL-3, an RNA methyltransferase, plays a key role in the initiation and progression
of many types of cancer. It is responsible for the deposition of m6A modification
on mRNA and long non-coding RNA (lncRNA) targets to regulate their stability, splicing,
transport and translation.;
Molecule name : STC -15; STC15;
NCI Metathesaurus CUI : CL1906495;
Origin ID : C199585;
concept_is_in_subset
- has_target
